Efficacy of aliskiren/hydrochlorothiazide single-pill combinations in aliskiren non-responders.

Georg Nickenig, Vladimir Simanenkov, Giuseppe Lembo, Pablo Rodriguez, Thomas Salko, Shannon Ritter, Jack Zhang

Research output: Contribution to journalArticle

Abstract

OBJECTIVES: To evaluate the efficacy, safety and tolerability of a single-pill combination of the direct renin inhibitor aliskiren and hydrochlorothiazide (HCT) in patients with hypertension and an inadequate BP response to aliskiren monotherapy (mean sitting diastolic BP [msDBP] > 90 and <or = 110 mmHg following 4 weeks of aliskiren 300 mg). METHODS: In this study, 880 patients with hypertension and an inadequate BP response to aliskiren monotherapy were randomized to once-daily, double-blind treatment with a single-pill combination of aliskiren/HCT 300/25 mg or 300/12.5 mg, or aliskiren 300 mg monotherapy. At the week 8 endpoint, least-squares mean changes in mean sitting systolic/diastolic BP (msSBP/DBP) from baseline were analyzed for the intent-to-treat population. RESULTS: Aliskiren/HCT 300/25 mg and 300/12.5 mg provided significantly greater msSBP/DBP reductions from baseline (15.9/11.0 mmHg and 13.5/10.5 mmHg, respectively) than aliskiren 300 mg alone (8.0/7.4 mmHg; both p

Original languageEnglish
Pages (from-to)31-40
Number of pages10
JournalBlood Pressure, Supplement
Volume2
Publication statusPublished - Dec 2008

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Efficacy of aliskiren/hydrochlorothiazide single-pill combinations in aliskiren non-responders.'. Together they form a unique fingerprint.

  • Cite this

    Nickenig, G., Simanenkov, V., Lembo, G., Rodriguez, P., Salko, T., Ritter, S., & Zhang, J. (2008). Efficacy of aliskiren/hydrochlorothiazide single-pill combinations in aliskiren non-responders. Blood Pressure, Supplement, 2, 31-40.